<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies have shown that patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) have increased <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the urinary excretion of <z:chebi fb="0" ids="28667">11-dehydro thromboxane B2</z:chebi> (11-DH-<z:chebi fb="0" ids="26996">TXB</z:chebi>(2) and isoprostane F(2alpha)III (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IPF</z:e>(2alpha)III), reflecting platelet activation and <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation in vivo, and plasma soluble markers of endothelial cell, platelet and blood coagulation activation: soluble vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (sVCAM-1), P- and E-selectin (sPsel and sEsel), F1 + 2 fragment of prothrombin (F1 + 2), thrombin-antithrombin complexes (TAT) and D-Dimer (DD) </plain></SENT>
<SENT sid="2" pm="."><plain>We studied 79 patients with aPL (47 with previous <z:mp ids='MP_0005048'>thrombosis</z:mp>), 45 healthy volunteers (<z:mpath ids='MPATH_458'>normal</z:mpath> controls, NC), 12 patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) without aPL and a <z:mp ids='MP_0005048'>thrombosis</z:mp> control group (TCG) without <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> (n = 16) </plain></SENT>
<SENT sid="3" pm="."><plain>Urinary levels (mean, range) of <z:chebi fb="0" ids="23899">eicosanoids</z:chebi> and isoeicosanoids were significantly increased in 39 patients with aPL compared with 25 NC, 11-DH-<z:chebi fb="0" ids="26996">TXB</z:chebi>(2) 164.0 ng/mmol <z:chebi fb="0" ids="16737">creatinine</z:chebi> (9.5-1162.8) versus 43.4 ng/mmol <z:chebi fb="0" ids="16737">creatinine</z:chebi> (4.2-87.6), P &lt; 0.001; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IPF</z:e>(2alpha)III 56.9 pg/mg <z:chebi fb="0" ids="16737">creatinine</z:chebi> (5.5-388.7) versus 27.0 pg/mg <z:chebi fb="0" ids="16737">creatinine</z:chebi> (4.6-87.6), P = 0.03 </plain></SENT>
<SENT sid="4" pm="."><plain>Both metabolites were significantly correlated (rho = 0.49, P = 0.014), but none correlated with any clinical manifestation or antibody profile </plain></SENT>
<SENT sid="5" pm="."><plain>The aPL group presented increased levels of sPsel, sEsel, sVCAM-1, TAT, F1 + 2 and DD, but any soluble marker correlated with IPF2alphaIII </plain></SENT>
<SENT sid="6" pm="."><plain>Urinary 11-DH-<z:chebi fb="0" ids="26996">TXB</z:chebi>(2) correlated with sPsel (rho = 0.39, P = 0.04) </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with SLE controls, the SLE group with aPL had higher levels of F1 + 2 </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma levels of F1 + 2 and DD were significantly increased and a trend to higher sPsel was found in aPL patients with <z:mp ids='MP_0005048'>thrombosis</z:mp> compared with the TCG </plain></SENT>
<SENT sid="9" pm="."><plain>Platelet activation, <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation and blood coagulation activation seem to be important in the pathophysiology of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>